FDA Generic Labeling Rule Could Help Pfizer In Reglan Product Liability Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Alabama Supreme Court is reconsidering its decision holding brand-name manufacturers liable for injuries caused by generics; Pfizer argues that FDA’s forthcoming proposed rule would eliminate concerns that no company could be held liable for injuries from a generic.